Melanoma Insights for Professionals

As melanoma in situ (MIS) diagnoses rise, concerns about overdiagnosis are growing — with real implications for patients, clinicians and the health system.In this episode of our podcast Melanoma Insights for Professionals, experts from dermatology, pathology, psychology and research come together to explore the drivers of overdiagnosis, the psychological impact of an MIS label, and the role of emerging diagnostic tools and data.This podcast is suitable for multidisciplinary specialist, primary care physicians and other healthcare professionals.SPEAKERSDr Peter Ferguson - Pathologist, Royal Prince Alfred Hospital and Melanoma Institute AustraliaDr Christoph Sinz - Confocal Microscopy Dermatologist, Melanoma Institute AustraliaClaire Gore - Senior Clinical Psychologist, Melanoma Institute AustraliaDr Ismael Vergara - Senior Computational Biologist, Melanoma Institute Australia | Adjunct Senior Lecturer, The University of SydneyRESOURCES MIA’s Patient Guides (e.g. Your Guide to Melanoma In-Situ) MIA’s Patient Fact Sheets (e.g. Scanxiety)REFERENCESBjørch MF, Gram EG, Brodersen JB Overdiagnosis in malignant melanoma: a scoping review BMJ Evidence-Based Medicine 2024;29:17-28.Cramb SM, Duncan EW, Aitken JF, Soyer HP, Mengersen KL, Baade PD. Geographical patterns in melanoma incidence across Australia: Can thickness differentials reveal the key drivers? Ann Cancer Epidemiol 2020;4:11Daniel Lindsay, Katy J L Bell, Catherine M Olsen, David C Whiteman, Thanya Pathirana, Louisa G Collins, Estimating the magnitude and healthcare costs of melanoma in situand thin invasive melanoma overdiagnosis in Australia British Journal of Dermatology, 2024;191(6): 906–913,Patel VR, Roberson ML, Pignone MP, Adamson AS. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA Dermatol.2023;159(7):703–710.Please note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.

In this episode, we explore how melanoma risk prediction tools are transforming clinical decision-making for newly diagnosed patients. These tools, developed by Melanoma Institute Australia and freely available at melanomarisk.org.au, help clinicians tailor care and improve outcomes.Our multidisciplinary experts provide practical guidance on using tools to predict sentinel node metastasis, recurrence risk and more. Through real-world case examples and expert insights, this episode offers valuable strategies for integrating personalised risk assessment into your practice.This podcast is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals.Resources:Melanoma Risk Prediction CalculatorsMIA's Patient ResourcesMelanoma Education PortalSpeakers:Prof Anne Cust - Cancer Epidemiologist and Faculty Member, Melanoma Institute Australia | Interim Director, Daffodil Centre | Chair, Cancer Council National Skin Cancer CommitteeA/Prof Alex Varey - Plastic and Reconstructive Surgeon, Melanoma Institute Australia and Westmead Hospital | Clinical Associate Professor, The University of SydneyA/Prof Linda Martin - Director of Dermatology Services, Melanoma Institute Australia | Staff Specialist, Sydney Children’s Hospital | Associate Professor of Dermatology, University of NSWPlease note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.

In this episode of Melanoma Insights for Professionals, we explore the evolving role of sentinel node biopsy (SNB) in melanoma management—particularly in the modern context of perioperative drug therapy.Our expert panel unpacks current evidence, shifting guidelines and real-world clinical considerations influencing when and why SNB is performed. Topics include prognostic value, surgical decision-making, pathological assessment, patient-centred perspectives and the impact of new treatment approaches on traditional staging practices.This podcast is produced by Melanoma Institute Australia and is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals.RESOURCES: Melanoma Risk Prediction Tools Patient brochure on SNB MIA's Melanoma Education Portal (Clinicians only)SPEAKERS:A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of SydneyA/Prof Robyn Saw - Surgical Oncologist, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of SydneyA/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of SydneyDr Robert Rawson - Pathologist, Melanoma Institute Australia |Tissue Pathology Staff Specialist, Royal Prince Alfred HospitalPlease note that this podcast was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.

In this episode of Melanoma Insights for Professionals, we explore the cutting-edge role of artificial intelligence (AI) in diagnosing melanoma.Join Dermatologists Prof Pascale Guitera and Prof Victoria Mar and Pathologist Dr Nigel Mayer as they unpack how AI is transforming clinical practice—from lesion detection and triage to deep learning in pathology and improving clinical education. Discover the promise, limitations and ethical considerations of integrating AI into dermatology and pathology, and hear what's next on the horizon for both clinicians and patients.This podcast is suitable for multidisciplinary specialists, primary care physicians, researchers and other healthcare professionals.SPEAKERSProf Pascale Guitera - Dermatologist and Education Committee Chair, Melanoma Institute Australia | Director, Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital Prof Victoria Mar - Director, Victorian Melanoma Service at The Alfred | Professor of DermatoOncology, the School of Public Health and Preventive Medicine, Monash UniversityDr Nigel Maher - Pathologist, Melanoma Institute Australia | Chair of the AI Working Group, Royal College of Pathologists of AustralasiaPlease note that this podcast was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.For more practice-changing clinical education, visit the Melanoma Education Portal.

In this special podcast recorded from the 2024 Australasian Melanoma Conference, we hear from our international keynote speakers, Prof Susan Swetter and Prof Olivier Michelin, about what excites them in the field of melanoma research. Interviewed by AMC2024 Co-Chairs, Prof Georgina Long AO and Prof Richard Scolyer AO, our guests provide their multidisciplinary perspectives and highlight the importance of working together to make an impact in melanoma prevention and patient care. Dermatologist Prof Swetter discusses the evolving role of AI in dermatology and the clinical diagnosis of melanoma, and highlights the opportunity for improved prevention strategies in the US to reduce the incidence of melanoma. Prof Michelin explores how we’re tackling advanced melanoma, in particular to maximize our current treatment tools and manage drug toxicities. He also discusses expanding access to neoadjuvant therapies and the potential of TIL therapies, alongside AI advancements in histopathological diagnosis to personalise treatment approaches. This podcast is suitable for multidisciplinary healthcare professionals and researchers. SPEAKERS Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney |2024 Joint Australian of the Year Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney |2024 Joint Australian of the Year Prof Susan Swetter - Professor of Dermatology, Co-Director of the Pigmented Lesion/Melanoma and Cutaneous Oncology Programs, Stanford University Medical Center and Cancer Institute | Chair, National Comprehensive Cancer Network Melanoma Panel Prof Olivier Michelin - Chair, Department of Oncology and the Precision Oncology Service, Geneva University Hospital | Co-Director, Swiss Cancer Centre Léman| Vice-Coordinator, Translational Research Centre in Onco-Hematology Please note that this podcast was accurate at the time of recording (October 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Comprehensive infrastructure is essential to driving research progress and improving patient care. In this podcast, A/Prof Sydney Ch’ng leads an insightful discussion on the groundbreaking research infrastructure that underpins the many groundbreaking achievements at Melanoma Institute Australia. The discussion highlights the Institute’s clinical trial program, translational research, biospecimen bank and melanoma research database, offering a closer look at the critical elements driving progress. This podcast is suitable for multidisciplinary healthcare professionals, researchers and clinical trials staff. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Helen Rizos - Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia A/Prof Serigne Lo - Senior Biostatistician, Melanoma Institute Australia | Associate Professor of Biostatistics, The University of Sydney Maria Gonzalez - Director of Clinical Care, Melanoma Institute Australia Dr Nicole Caixeiro - Head of the Biospecimen Bank, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (August 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. LINKS 2024 Australasian Melanoma Conference Melanoma Education Program MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too. In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA’s Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions. This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by Melanoma Institute Australia. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney PUBLICATIONS Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604 Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823. FURTHER EDUCATION Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Conference: 2024 Australasian Melanoma Conference Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Biomarkers are revolutionising our understanding of melanoma by providing valuable information about a patient's unique tumour characteristics which can help guide clinical decision making. In this podcast, A/Prof Alex Menzies leads a multidisciplinary discussion on the current state of biomarker application and future prospects of biomarkers in melanoma care. They discuss emerging liquid biomarkers, such as ctDNA, MIA’s personalised immunotherapy platform that is trying to predict the likelihood of response and select patients for treatment, and the role of the gut microbiome as a potential biomarker in response and toxicity. This podcast from Melanoma Institute Australia is suitable for Medical Oncologists, Surgical Oncologists, Researchers, GPs and other healthcare professionals. LINKS: 2024 Australasian Melanoma Conference Melanoma Risk Prediction Tools Melanoma Education Portal SPEAKERS A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia and Blacktown Hospital | Research Scientist, Melanoma Institute Australia and The University of Sydney Prof Helen Rizos - Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia A/Prof James Wilmott - Senior Scientist, Charles Perkins Centre, The University of Sydney| Faculty Member, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (April 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane. In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch’ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. Register now to attend the 2024 Australasian Melanoma Conference, hosted by Melanoma Institute Australia. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Raewyn Campbell - Rhinologist and Anterior Skull Base Surgeon |Associate Professor, Macquarie University Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

Diagnostic uncertainty in the context of cutaneous melanoma can have significant impact on patient care. In this podcast, our multidisciplinary experts, led by Dr Adrian Quek, discuss the challenges faced in classifying melanocytic lesions that fall into a diagnostic grey area, and explore the terminology, evolving classifications and the impact of diagnostic uncertainty on patient outcomes. From molecular changes to clinical perspectives, this engaging discussion provides a comprehensive exploration of the complexities surrounding borderline lesions, and emphasises the need for experienced multidisciplinary professionals in ensuring accurate diagnoses and ideal management. This podcast is suitable for Pathologists, Dermatologists, Surgeons, Oncologists, GPs and other healthcare professionals. Register now to attend the ⁠2024 Australasian Melanoma Conference⁠, hosted by Melanoma Institute Australia. RESOURCES Video: How to diagnose borderline cutaneous melanocytic lesions Paper: Yeh, I. New and evolving concepts of melanocytic nevi and melanocytomas. Modern Pathology. 2020;33:1-14. Nevus/Melanocytoma/Melanoma: An Emerging Paradigm for Classification of Melanocytic Neoplasms?. Arch Pathol Lab Med. 2011;135(3): 300–306. SPEAKERS Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and Chatswood Skin Cancer Clinic A/Prof Robyn Saw - General Surgeon, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of Sydney Prof H. Peter Soyer - Chair in Dermatology and Director of the Dermatology Research Centre, The University of Queensland Dr Andrew Colebatch - Staff Specialist in Anatomical Pathology, Royal Prince Alfred Hospital Please note that this podcast was accurate at the time of recording (November 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. For more clinical education from MIA, sign up to the Melanoma Education Portal.

With the advent of effective medical therapies for melanoma, a pertinent question has arisen: When should we scan our patients? In this podcast, our multidisciplinary experts, led by A/Prof Sydney Ch’ng, discuss the balance of whether we should be more aggressive in our pursuit of identifying potential metastases or exercise caution to avoid unnecessary scans, radiation exposure and patient anxiety. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, GPs, Oncology Nurses and other healthcare professionals. RESOURCES Melanoma Risk Prediction Tools SPEAKERS A/Prof Sydney Ch’ng -  Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia, Associate Professor of Surgery, The University of Sydney  A/Prof Alexander Menzies -  Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney Dr Edward Hsiao - Radiologist and Nuclear Medicine Specialist, Mater Imaging Dr Kevin London - Nuclear Medicine Specialist, The Children’s Hospital at Westmead | Clinical Senior Lecturer, The University of Sydney Please note that this podcast was accurate at the time of recording (September 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. 

Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA’s Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch’ng discuss: the history of SNB in the management of melanoma its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence. This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Our latest podcast explores the innovative approach of neoadjuvant  immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of  melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential  benefits for melanoma patients are being realised. Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates. In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss: the benefits of checkpoint inhibitor immunotherapy the role of the pathologist in the assessment of neoadjuvant tissue the impact of surgical decision-making as neoadjuvant becomes mainstay treatment options for treatment-refractory patients the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer. The discussion concludes with case studies to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists,  Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other  healthcare professionals. SPEAKERS: Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and  Translational Research, Melanoma Institute Australia and Royal North  Shore Hospital, The University of Sydney Prof Richard Scolyer AO - Co-Medical Director,  Melanoma Institute Australia | Pathologist, Melanoma Institute  Australia, Senior Staff Specialist, Royal Prince Alfred Hospital |  Clinical Professor, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist,  Melanoma Institute Australia, Royal North Shore and Mater Hospitals |  Associate Professor of Melanoma Medical Oncology, The University of  Sydney A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal  Prince Alfred Hospital, The University of Sydney KEY CLINICAL TRIALS SWOG PRADO OpACIN-neo NADINA FURTHER EDUCATION The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists  Please note that this podcast was accurate at the time of recording  (February 2023) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians. In this podcast, Dr Michael Rtshiladze leads a multidisciplinary  discussion to unravel our understanding of the pathology, diagnosis and  management of lentigo maligna, including: clinical and histological presentation tools to diagnose and monitor lesions the impact of different types of biopsies the importance of mapping the extent of lesions the challenge of surgical management in cosmetically sensitive areas the role of radiation therapy and topical treatments when to refer your patient. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, General Surgeons,  Dermatologists, Oncologists, Pathologists, GPs, Nurses and other  healthcare professionals. SPEAKERS Dr Michael Rtshiladze - Plastic and Reconstructive  Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The  Prince of Wales Hospital, St George Hospital and Sydney Children’s  Hospital Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Pascale Guitera - Dermatologist, Melanoma  Institute Australia | Director, Sydney Melanoma Diagnostic Centre at  Royal Prince Alfred Hospital | Professorial Research Fellow, The  University of Sydney Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney RESOURCE AND REFERENCE Lentigo Maligna Patient Information Brochure Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF & Ch'ng S. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol. 2021 May;47(5):1145-1151. Please note that this podcast was accurate at the time of recording  (December 2022) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital. In this podcast, A/Prof Matteo Carlino interviews fellow Medical  Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including: presentation and diagnostic process current treatment options and rationale for local therapy in early melanoma determining which patients are suitable for screening for metastatic disease developing a surveillance plan based on risk of recurrence the different activity of systemic therapy in uveal versus cutaneous melanoma importance of the multidisciplinary team activity of tebentafusp in advanced uveal melanoma the current clinical trial landscape. This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma  Institute Australia, Westmead and Blacktown Hospitals Clinical  Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Max Conway - Ophthalmologist, Save Sight Institute, Sydney Eye Hospital and The University of Sydney RESOURCES Early Ocular Melanoma Patient Information Brochure Advanced Ocular Melanoma Patient Information Brochure Melanoma Education Portal Please note that this podcast was accurate at the time of recording  (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.

Treating clinicians rely on pathology to help diagnose and stage their patient which fundamentally determines the treatment management  plan. Therefore, it is incredibly important to get it right in the first place. In this engaging podcast aimed at GPs, our multidisciplinary experts discuss: Why can it be challenging to get the pathology right? What clinical information is important to include on the pathology request form? How is the pathology report structured? How is the specimen processed? What biopsy is key to maximising the diagnostic and prognostic interpretation of the pathology? Are partial biopsies ever appropriate? What implications does the type of biopsy have for subsequent surgery? When does a GP need to refer their patient? The discussion is concluded with two case studies to summarise key learnings. This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals. SPEAKERS Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and The Chatswood Skin Cancer Clinic Dr Alison Potter - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Dr Nigel Maher - McMurtrie Cancer Pathology Fellow, Melanoma Institute Australia A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney Dr Niamh-Anna O’Sullivan - Specialist Dermatologist, Melanoma Institute Australia HOST Danielle Fischer - Education Program Manager, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape  and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

The role of pathology in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the pathologist for accurate diagnoses and critical pathological information, we decided to reach out to our clinical melanoma community to ask them for their critical pathology questions.  In this podcast, Prof John Thompson AO and Prof Fergal Moloney pick at the brain of the world's leading melanoma Pathologist, Prof Richard Scolyer AO, as they discuss:  The clinical information needed to aid diagnosis  The role of artificial intelligence and computing in pathology  Overdiagnosis of melanoma  The problem of partial biopsies  Diagnosing borderline lesions  What is a melanocytoma and how should it be managed  What is an irritated naevus  Dysplastic naevi and appropriate management  This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals.  SPEAKERS  Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney  Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Member, Melanoma Institute Australia  Prof Fergal Moloney - Consultant Dermatologist, Melanoma Institute Australia and Mater Misericordiae University Hospital | Clinical Professor, University College, Dublin  Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  For more practice-changing education, visit our Melanoma Education Portal.  MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of and manage. In this podcast, A/Prof Carlino interviews fellow Medical Oncologist Prof Georgina Long AO on the adverse events/toxicities associated with targeted therapies (combination BRAF/MEK inhibitors) and immunotherapies (anti-PD-1, anti-LAG-3 and anti-CTLA-4), particularly in melanoma, and how they should be managed. This podcast is suitable for Oncologists, Emergency Medicine Physicians, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney Please note that this podcast was accurate at the time of recording (May 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

The field of melanoma has experienced a paradigm shift in recent years, with advancements in both diagnosis and management driving improved patient outcomes. Through the power of research, day-to-day practice continues to be transformed.  In this lively podcast, two of Australia's leading melanoma experts Prof Richard Scolyer AO and Prof Georgina Long AO discuss:  how melanoma management has transformed in the last decade  the challenge of diagnosing melanoma for clinicians and pathologists, and practical ways to help make accurate assessments  the importance of staging  why sentinel node biopsies are important  how multidisciplinary care enhances patient outcomes  emerging evidence on neoadjuvant treatment and how this will change the way melanoma is managed  the challenge of supportive care and where to find help.  In this practical discussion, resources and further education for deeper dives into specific topics are also mentioned, with links below.  This podcast is suitable for oncologists, surgeons, dermatologists, skin cancer GPs, GPs, nurses and other healthcare professionals.  SPEAKERS  Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney  Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney  LINKS TO RESOURCES  Melanoma Risk Prediction Tools  Prof John Thompson's presentation: Update on melanoma staging  Order or download a pocket-sized Melanoma Staging Card  Prof Richard Scolyer's presentation: Melanoma near misses: Clues to diagnosis  Dermoscopy module: Techniques in melanoma assessment  Interactive game: DermChallenge: Management.  Debate: To shave or not to shave when biopsying melanoma  Podcast: Multidisciplinary management of primary melanoma  Presentation by Dr Rob Rawson and Dr Michael Rtshiladze: The melanoma pathology report and its impact on clinical management  Wiki melanoma guidelines: Clinical practice guidelines for the diagnosis and management of melanoma  Interactive module: The current role of sentinel node biopsy in the management of melanoma  Debate: The role of sentinel node biopsy is overstated in melanoma  SNB Melanoma Risk Calculator  Visit the Melanoma Education Portal for the full list of resources.

Managing in-transit melanoma can be challenging, and it presents and progresses as a heterogeneous disease. Multidisciplinary care is recommended for this complex disease to determine the optimal outcome for the patient.  In this engaging podcast, our multidisciplinary expert panel - featuring a Dermatologist, Surgeon and Medical Oncologist - discuss:  the clinical presentation of in-transit melanoma  importance of biopsy and imaging  local therapy options including surgical resection, topical diphencyprone, radiotherapy, injectable agents and isolated limb infusion systemic therapy options in the adjuvant and unresectable settings.  In addition, the panel reviews a case study to put learnings into practice.  This podcast is suitable for Surgeons, Medical Oncologists, Dermatologists, Skin Cancer GPs, GPs, Nurses and other healthcare professionals.  Please note that this podcast was accurate at the time of recording (October 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  SPEAKERS  A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney  A/Prof Robyn Saw - General Surgeon, Melanoma Institute Australia | Associate Professor in Surgery, The University of Sydney | Head of Department, Melanoma and Surgical Oncology, Royal Prince Alfred Hospital  Prof Diona Damian - Professor of Dermatology, The University of Sydney | Clinical Academic, Royal Prince Alfred Hospital |Associate, Melanoma Institute Australia